GlassScriptPhysician profile
Candace B Holladay
NPI 1194715243
$753.40
in general payments reported to CMS, 2019-2025
14 companies · $96.56 in 2025
The $96.56 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $210 · 2020: $125 · 2021: $27.68 · 2022: $122 · 2023: $172 · 2025: $96.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $268.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $201.48 | 2019-2022 | |
| Sobi, INC | $111.50 | 2020-2023 | |
| Sumitomo Pharma America, INC. | $96.56 | 2025 | Myfembree |
| Sanofi Pasteur INC. | $65.88 | 2022-2023 | |
| Tris Pharma INC | $57.67 | 2022 | |
| Cranial Technologies, INC | $57.51 | 2022-2023 | Doc Band |
| Kaleo, INC. | $35.15 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $23.25 | 2023 | Flumist Quadrivalent |
| Genentech USA, INC. | $23.20 | 2019 | |
| Merck Sharp & Dohme LLC | $19.79 | 2023 | Vaxneuvance, Gardasil 9, Vaxelis |
| Shire North American Group INC | $17.38 | 2019 | |
| Allegis Pharmaceuticals, LLC | $16.58 | 2023 | Spinosad |
| Glaxosmithkline, LLC. | $13.90 | 2020 | |
| Supernus Pharmaceuticals, INC. | $13.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Candace Holladay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.